Abstract
No public abstract is available from the verified source records.
Jeffrey M Sturek, Anna Podolanczuk, Riley T Hannan, Andrew H Limper, Ivan O Rosas, Gisli Jenkins, Jesse Roman, Victor J Thannickal, Imre Noth
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Progressive pulmonary fibrosis: an expert group consensus statement
10.1183/13993003.03187-2021 · 2023
Relationship between idiopathic interstitial pneumonias (IIPs) and connective tissue disease-related interstitial lung disease (CTD-ILD): a narrative review
10.1016/j.resinv.2024.03.006 · 2024
Unresolved referenced work
Kept as external metadata until matched
Clinical advances in the diagnosis and therapy of the interstitial lung diseases
10.1164/rccm.200503-483oe · 2005
Idiopathic pulmonary fibrosis: new insights in its pathogenesis
10.1016/s1357-2725(02)00091-2 · 2002
Pathogenesis of “fibrosis” in interstitial pneumonia: an electron microscopic study
10.1016/s0046-8177(85)80279-3 · 1985
Abnormal re-epithelialization and lung remodeling in idiopathic pulmonary fibrosis: the role of deltaN-p63
10.1097/01.lab.0000032380.82232.67 · 2002
Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis
10.1126/scitranslmed.3005964 · 2013
Blood transcriptomics predicts progression of pulmonary fibrosis and associated natural killer cells
10.1164/rccm.202008-3093oc · 2021
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
Proteomic biomarkers of survival in idiopathic pulmonary fibrosis
10.1164/rccm.202301-0117oc · 2024
PCSK6 and survival in idiopathic pulmonary fibrosis
10.1164/rccm.202205-0845oc · 2023
Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial
10.1186/s12890-022-02281-8 · 2022
TOLLIP, MUC5B, and the response to n-acetylcysteine among individuals with idiopathic pulmonary fibrosis
10.1164/rccm.201505-1010oc · 2015
Animal models of fibrotic lung disease
10.1165/rcmb.2013-0094tr · 2013
Single-cell RNA sequencing identifies diverse roles of epithelial cells in idiopathic pulmonary fibrosis
10.1172/jci.insight.90558 · 2016
Single-cell transcriptomic analysis of human lung provides insights into the pathobiology of pulmonary fibrosis
10.1164/rccm.201712-2410oc · 2019
Proliferating SPP1/MERTK-expressing macrophages in idiopathic pulmonary fibrosis
10.1183/13993003.02441-2018 · 2019
Single-cell RNA-seq reveals ectopic and aberrant lung-resident cell populations in idiopathic pulmonary fibrosis
10.1126/sciadv.aba1983 · 2020
Single-cell RNA sequencing reveals profibrotic roles of distinct epithelial and mesenchymal lineages in pulmonary fibrosis
10.1126/sciadv.aba1972 · 2020
Collagen-producing lung cell atlas identifies multiple subsets with distinct localization and relevance to fibrosis
10.1038/s41467-020-15647-5 · 2020
Single-cell RNA sequencing identifies G-protein coupled receptor 87 as a basal cell marker expressed in distal honeycomb cysts in idiopathic pulmonary fibrosis
10.1183/13993003.02373-2021 · 2022
Integrated single-cell atlas of endothelial cells of the human lung
10.1161/circulationaha.120.052318 · 2021
Cell-type-specific and disease-associated expression quantitative trait loci in the human lung
10.1038/s41588-024-01702-0 · 2024
Single-cell reconstruction of human basal cell diversity in normal and idiopathic pulmonary fibrosis lungs
10.1164/rccm.201904-0792oc · 2020
Senescence of alveolar type 2 cells drives progressive pulmonary fibrosis
10.1164/rccm.202004-1274oc · 2021
Precision cut lung slices: an integrated ex vivo model for studying lung physiology, pharmacology, disease pathogenesis and drug discovery
10.1186/s12931-024-02855-6 · 2024
An ex vivo model to induce early fibrosis-like changes in human precision-cut lung slices
10.1152/ajplung.00084.2017 · 2017
Precision-cut lung slices: emerging tools for preclinical and translational lung research: an official American Thoracic Society Workshop Report
10.1165/rcmb.2024-0479st · 2025
Human alveolar type 2 epithelium transdifferentiates into metaplastic KRT5(+) basal cells
10.1038/s41556-021-00809-4 · 2022
Ex vivo tissue perturbations coupled to single-cell RNA-seq reveal multilineage cell circuit dynamics in human lung fibrogenesis
10.1126/scitranslmed.adh0908 · 2023
Hypoxia-inducible factor 2 regulates alveolar regeneration after repetitive injury in three-dimensional cellular and in vivo models
10.1126/scitranslmed.adk8623 · 2025
Airway basal cells show a dedifferentiated KRT17(high)Phenotype and promote fibrosis in idiopathic pulmonary fibrosis
10.1038/s41467-022-33193-0 · 2022
The UIP/IPF fibroblastic focus is a collagen biosynthesis factory embedded in a distinct extracellular matrix
10.1172/jci.insight.156115 · 2022
Alveolar fibroblast lineage orchestrates lung inflammation and fibrosis
10.1038/s41586-024-07660-1 · 2024
Multiplatform single-cell analysis identifies immune cell types enhanced in pulmonary fibrosis
10.1165/rcmb.2021-0418oc · 2022
Unresolved referenced work
2021
Mapping spatially resolved transcriptomes in human and mouse pulmonary fibrosis
10.1038/s41588-024-01819-2 · 2024
Spatial transcriptomic characterization of pathologic niches in IPF
10.1126/sciadv.adl5473 · 2024
Spatial transcriptomics identifies molecular niche dysregulation associated with distal lung remodeling in pulmonary fibrosis
10.1038/s41588-025-02080-x · 2025
Digital quantification of p16-positive foci in fibrotic interstitial lung disease is associated with a phenotype of idiopathic pulmonary fibrosis with reduced survival
10.1186/s12931-022-02067-w · 2022
Host-microbial interactions in idiopathic pulmonary fibrosis
10.1164/rccm.201607-1408oc · doi-reference
Disease modeling of pulmonary fibrosis using human pluripotent stem cell-derived alveolar organoids
10.1016/j.stemcr.2021.10.015 · doi-reference
Adaptive organoid-based precision therapy study in pancreatic cancer (ADOPT): a phase II single-arm study to evaluate the efficacy of patient-derived organoid (PDO)-directed therapy in advanced pancreatic ductal adenocarcinoma (PDAC)
10.1200/jco.2025.43.16_suppl.tps4232 · doi-reference
Pancreatic organoids as cancer avatars for true personalized medicine
10.1016/j.addr.2025.115642 · doi-reference
Lung organoids: current uses and future promise
10.1242/dev.140103 · doi-reference
Modeling of fibrotic lung disease using 3D organoids derived from human pluripotent stem cells
10.1016/j.celrep.2019.05.077 · doi-reference
Clinical trial design in the era of precision medicine
10.1186/s13073-022-01102-1 · doi-reference
Unequal representation of genetic variation across ancestry groups creates healthcare inequality in the application of precision medicine
10.1186/s13059-016-1016-y · doi-reference
Health disparities and associated social determinants of health in interstitial lung disease: a narrative review
10.1183/16000617.0176-2024 · doi-reference
Lung-on-a-chip: the future of respiratory disease models and pharmacological studies
10.1080/07388551.2019.1710458 · doi-reference
Lung organoids: advances in generation and 3D-visualization
10.1007/s00418-020-01955-w · doi-reference
Extracellular matrix scaffolds for tissue engineering and regenerative medicine
10.2174/1574888x11666160905092513 · doi-reference
Cigarette smoke promotes dendritic cell accumulation in COPD; a Lung Tissue Research Consortium study
10.1186/1465-9921-11-45 · doi-reference
Relationship between lung function impairment and health-related quality of life in COPD and interstitial lung disease
10.1378/chest.11-1332 · doi-reference
Personalized medicine: applying ‘omics’ to lung fibrosis
10.2217/bmm.12.38 · doi-reference
Fibrosis: lessons from OMICS analyses of the human lung
10.1016/j.matbio.2018.03.014 · doi-reference
Molecular characterization of a precision-cut rat lung slice model for the evaluation of antifibrotic drugs
10.1152/ajplung.00339.2018 · doi-reference
Lessons from our patients: development of a warm autopsy program
10.1371/journal.pmed.0030234 · doi-reference
Surgical lung biopsy analyses differ by race and ethnicity in interstitial lung disease
10.1183/23120541.00870-2024 · doi-reference
Sex and racial differences in lung biopsies for interstitial lung diseases in Canada
10.1513/annalsats.202308-703rl · doi-reference
African-American race and mortality in interstitial lung disease: a multicentre propensity-matched analysis
10.1183/13993003.00255-2018 · doi-reference
Idiopathic pulmonary fibrosis
10.1056/nejmra1705751 · doi-reference
Bronchoalveolar lavage and lung biopsy in connective tissue diseases, to do or not to do?
10.1177/1759720x211059605 · doi-reference
The role of lung biopsy for diagnosis and prognosis of interstitial lung disease in systemic sclerosis: a systematic literature review
10.1186/s12931-024-02725-1 · doi-reference
Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline
10.1164/rccm.201807-1255st · doi-reference
Prognostic significance of bronchoalveolar lavage cellular analysis in patients with acute exacerbation of interstitial lung disease
10.1016/j.rmed.2021.106534 · doi-reference
Serum high-mobility group box 1 is associated with the onset and severity of acute exacerbation of idiopathic pulmonary fibrosis
10.1111/resp.13634 · doi-reference
C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis
10.1164/rccm.201309-1592oc · doi-reference
High levels of IL-6 and IL-8 characterize early-on idiopathic pulmonary fibrosis acute exacerbations
10.1016/j.cyto.2017.08.019 · doi-reference
Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis
10.1164/rccm.200810-1596oc · doi-reference
Molecular differences between stable idiopathic pulmonary fibrosis and its acute exacerbation
10.52586/5038 · doi-reference
Serum soluble isoform of receptor for advanced glycation end product is a predictive biomarker for acute exacerbation of idiopathic pulmonary fibrosis: a German and Japanese cohort study
10.1186/s12931-024-03014-7 · doi-reference
Lipocalin-2 as a prognostic marker in patients with acute exacerbation of idiopathic pulmonary fibrosis
10.1186/s12931-024-02825-y · doi-reference
Elevated expression of growth differentiation factor-15 is associated with acute exacerbation of idiopathic pulmonary fibrosis
10.3389/fimmu.2022.891448 · doi-reference
Impact of serum SP-A and SP-D levels on comparison and prognosis of idiopathic pulmonary fibrosis: a systematic review and meta-analysis
10.1097/md.0000000000007083 · doi-reference
Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis
10.1152/ajplung.90637.2008 · doi-reference
Changes in blood Krebs von den Lungen-6 predict the mortality of patients with acute exacerbation of interstitial lung disease
10.1038/s41598-022-08965-9 · doi-reference
Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis
10.1016/j.rmed.2014.04.009 · doi-reference
Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline
10.1164/rccm.202202-0399st · doi-reference
Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial
10.1016/s2213-2600(21)00354-4 · doi-reference